Thai pharmaceutical company Siam Bioscience Group confirmed with the Bangkok Post that by 2022 the company plans to produce and sell three new drugs for cancer, kidney failure, and autoimmune diseases, both in Thailand and abroad.
Established in 2009, Siam Bioscience is owned by the Crown Property Bureau, a quasi-government agency responsible for managing the property of the crown of the Kingdom of Thailand. It has three Manufacturing facilities in Bang Yai, Nonthaburi. The company researches, develops and manufactures biopharmaceuticals with the aim of reducing Thailand’s dependency on imported active ingredients and drugs. It exports drugs to Cambodia, Myanmar, Laos and Sri Lanka.
Siam Bioscience has also entered into a partnership with Cuba’s Center for Molecular Immunology (CIM) to develop monoclonal antibodies to treat cancer and autoimmune diseases. The joint venture will enable innovative pharmaceuticals to have a more affordable price tag, improving Thailand’s access to modern Medical treatment.
(Source: Bangkok Post; OnCuba News)